Shopping Cart
Remove All
Your shopping cart is currently empty
MB076 is an innovative heterocyclic triazole designed with enhanced plasma stability. It effectively inhibits seven distinct Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with K i values less than 1 μM. Additionally, MB076 demonstrates a synergistic effect when combined with various cephalosporins to restore pBCSK(−) susceptibility [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | MB076 is an innovative heterocyclic triazole designed with enhanced plasma stability. It effectively inhibits seven distinct Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with K i values less than 1 μM. Additionally, MB076 demonstrates a synergistic effect when combined with various cephalosporins to restore pBCSK(−) susceptibility [1]. |
| In vitro | MB076 (compound B) demonstrates exceptional stability in human plasma at concentrations ranging from 0.5 to 5 μM over 48 hours, with a half-life (t1/2) of 29 hours, significantly exceeding the 9 hours observed for ADC-7/S02030 (PDB4U0X) [1]. Additionally, when combined at a concentration of 10 μg/mL with Ceftazidime (CAZ) and Cefotaxime (CTX) for 48 hours, MB076 synergistically restores drug sensitivity in pBCSK(-) [1]. Cell viability assays [1] conducted in human plasma with concentrations from 0.5 μM to 5 μM and an incubation period of 48 hours further confirm the compound’s outstanding stability. |
| Molecular Weight | 373.18 |
| Formula | C9H12BN7O5S2 |
| Cas No. | 2832966-95-5 |
| Smiles | C([C@H](NC(CSC=1SC(N)=NN1)=O)B(O)O)N2C=C(C(O)=O)N=N2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.